Clinical trials: Community Acquired Pneumonia (CAP)
Community Acquired Pneumonia, Pneumonia
Standardized Emergency Care for Community Acquired Pneumonia (CAP)
Community acquired pneumonia (CAP) is associated with a high in-hospital mortality. Standardization of diagnostics and adherence to sepsis bundles in the emergency department (ED) are associated with reduced mortality in patients…
- Conditions
- Community Acquired Pneumonia, Pneumonia, Infection
- Trial name
- NCT01963000
- Where
- Germany
- Volunteers
- 2,819 people
- Sponsor
- Klinikum Nürnberg
Community-acquired Pneumonia
Clarithromycin Treatment to Prevent Sepsis Progression in CAP (REACT)
The primary objective of the REACT randomized clinical trial (RCT) is to optimize the clinical benefit from adjunctive clarithromycin treatment shown in the ACCESS trial and to provide evidence for the clinical benefit of early…
- Trial name
- REACT (NCT06294600)
- Testing
- Clarithromycin 500mg, Tablets
- Where
- 24 sites in Greece
- Volunteers
- 330 people
- Sponsor
- Hellenic Institute for the Study of Sepsis
Community Acquired Pneumonia (CAP)
ItAlian ReGistry Of pNeumoniA in immUnocompromised paTients (ARGONAUT)
This multicentric, prospective study aims at: evaluating the prevalence, etiology, characteristics, and 1one-year outcomes of immunocompromised patients hospitalized for Community-Acquired Pneumonia (CAP); conducting biochemical…
- Trial name
- ARGONAUT (NCT06755814)
- Where
- Italy
- Volunteers
- 1,298 people
- Sponsor
- Societa Italiana di Pneumologia
Community Acquired Pneumonia
A Retrospective Study on Hospitalized Patients With Community-acquired Pneumonia in China (CAP-China)
The purpose of this study is to evaluate the disease burden of hospitalized patients with CAP and healthcare-associated pneumonia (HCAP) in real life of China .
- Trial name
- RSCAP-China (NCT02489578)
- Testing
- other
- Where
- China
- Volunteers
- 3,000 people
- Sponsor
- Capital Medical University
Community Acquired Pneumonia, Respiration Failure
A Molecular Toolkit for the Microbial Investigation of Severe Community Acquired Pneumonia
Severe community acquired pneumonia is common and associated with high mortality. Conventional microbiological diagnostics identify pathogens in approximately half of cases, which is inadequate for both clinical and…
- Conditions
- Community Acquired Pneumonia, Respiration Failure, Pneumonia
- Trial name
- S-CAP (NCT02963142)
- Where
- United Kingdom
- Volunteers
- 103 people, healthy volunteers welcome
- Sponsor
- Imperial College London
Community Acquired Pneumonia
Comparative Study of NXL103 Versus Comparator in Adults With Community Acquired Pneumonia
The purpose of this study is to compare the efficacy, safety and tolerance of 2 different dose levels of oral NXL103 with oral comparator in the treatment of community acquired pneumonia in adults
- Trial name
- NCT00653172
- Testing
- NXL103, comparator
- Where
- 60 sites in Chile, Croatia and 7 more
- Volunteers
- 302 people
- Sponsor
- Novexel Inc
Pneumonia, Sepsis
Study of Progression of Community Acquired Pneumonia in the Hospital
Pneumonia is a common infectious disease of the lung, often requiring treatment in the hospital. Clinical scoring systems are available, identifying patients not requiring hospitalization.
- Conditions
- Pneumonia, Sepsis, Shock, Septic
- Trial name
- PROGRESS (NCT02782013)
- Where
- 64 sites in Austria, Germany
- Volunteers
- 2,309 people
- Sponsor
- Pneumonia Research Network on Genetic Resistance and Susceptibility for the Evolution of Severe Seps
Sepsis
CLARITHROMYCIN TO PREVENT SECONDARY INFECTIONS IN PATIENTS WITH SEPSIS FOLLOWING LOWER RESPIRATORY TRACT INFECTIONS: THE CLASSIFY TRIAL
The goal of this clinical trial is to assess whether clarithromycin, given as an adjunct to standard-of-care antibiotic therapy, can reduce the risk of new infections and secondary sepsis in adult patients hospitalized with…
- Trial name
- CLASSIFY (NCT07834346)
- Testing
- clarithromycin
- Where
- 19 sites in Greece
- Volunteers
- 252 people
- Sponsor
- Hellenic Institute for the Study of Sepsis
Community-acquired Bacterial Pneumonia
Efficacy and Safety Study of Intravenous to Oral Solithromycin (CEM-101) Compared to Intravenous to Oral Moxifloxacin in Treatment of Patients With Community-Acquired Bacterial Pneumonia
This study will evaluate the safety and efficacy of an experimental antibiotic, solithromycin, in the treatment of adult patients with community-acquired pneumonia.
- Trial name
- SOLITAIRE-IV (NCT01968733)
- Testing
- Solithromycin, Moxifloxacin
- Where
- 270 sites in United States, Argentina and 24 more
- Volunteers
- 863 people
- Sponsor
- Melinta Therapeutics, Inc.
Community-acquired Pneumonia, CAP
Inhaled Lexofloxacin vs Usual Care for Treatment of Community-Acquired Pneumonia
This trial aims to determine whether treatment with inhaled levofloxacin (an antibiotic) is equal to systemic antibiotic treatment (usual care) for patients admitted to a hospital with community-acquired pneumonia in regards to…
- Conditions
- Community-acquired Pneumonia, CAP, Community Acquired Pneumonia, Pneumonia
- Trial name
- LANDCAP 2 (NCT07843017)
- Testing
- Inhaled levofloxacin, Standard-of-care / Usual care
- Volunteers
- 460 people
- Sponsor
- Copenhagen Respiratory Research
Community Acquired Pneumonia, Complicated Skin and Soft Tissue Infection
Retrospective Chart Review Study to Assess Characteristics, Treatment Outcomes and Resource Use of Adults Hospitalized for CAP and CSSTi Treated With Zinforo in Multiple Countries
MULTINATIONAL Retrospective Chart Review Study to Assess the Characteristics, Treatment Outcomes and Resource Use Among Adult Patients Hospitalized for Community-Acquired Pneumonia (CAP) or Complicated Skin and Soft Tissue…
- Trial name
- NCT04198571
- Testing
- Zinforo (ceftaroline fosamil)
- Where
- 26 sites in Brazil, Colombia and 5 more
- Volunteers
- 317 people
- Sponsor
- Pfizer
Community Acquired Pneumonia (CAP)
Comparing Hydrocortisone and Prednisolone for Community Acquired Pneumonia (CAP)
The goal of this cluster randomized controlled trial is to determine the optimal treatment for community aquired pneumonia (CAP).
- Trial name
- NCT06892197
- Testing
- Methylprednisolone (drug), hydrocortisone
- Where
- 14 sites in Denmark
- Volunteers
- 1,600 people
- Sponsor
- Copenhagen Respiratory Research
Community-Acquired Pneumonia (CAP)
A Study to Learn About How Well the Prevnar 20 Vaccine Works for Pneumonia in People Who Are 65 Years and Older
The purpose of this study is to learn about how well the Prevnar 20 vaccine (PCV20) stops invasive pneumococcal disease (a group of severe infections caused by a bacteria called Streptococcus pneumoniae), pneumococcal pneumonia…
- Trial name
- NCT06782282
- Where
- United States
- Volunteers
- 22,234,435 people
- Sponsor
- Pfizer
Chronic Obstructive Pulmonary Disease, Community-acquired Pneumonia
A Pre-post Intervention Study Evaluating Home-based Management of Patients With COPD or CAP
Risk of rehospitalization within 30 days of discharge is higher than 20% in patients with chronic obstructive pulmonary disease (COPD) and up to 20% for patients with community acquired pneumonia (CAP).
- Trial name
- NCT05009485
- Testing
- Current Health platform
- Sponsor
- Current Health
Community-Acquired Pneumonia (CAP), Pneumonia
Clinical Impact of Rapid Molecular Testing for Pathogens in Patients With Severe Acute Respiratory Illness : A Pragmatic Trial
Community-acquired pneumonia (CAP) is among the most common reasons for emergency department (ED) visits. A clear understanding of the likely pathogens is essential for the rapid institution of adequate antimicrobial therapy.
- Trial name
- CIRT-RMT-SARI (NCT06605352)
- Testing
- The BIOFIRE®FILMARRAY® Pneumonia Panel
- Where
- Taiwan
- Volunteers
- 800 people
- Sponsor
- National Taiwan University Clinical Trial Center
Pneumonia
PK Analysis of Moxifloxacin in the Treatment of CAP
At the Department of Infectious Diseases, Aarhus Denmark, moxifloxacin is used in the empirical treatment of severe community-acquired pneumonia (CAP).
- Trial name
- NCT01983839
- Where
- Denmark
- Volunteers
- 18 people
- Sponsor
- University of Aarhus
Community Acquired Pneumonia
Study to Compare Lefamulin to Moxifloxacin (With or Without Linezolid) for the Treatment of Adults With Pneumonia
This study evaluates the safety and efficacy of lefamulin, a pleuromutilin, for the treatment of adults with moderate to severe community-acquired bacterial pneumonia.
- Trial name
- LEAP (NCT02559310)
- Testing
- lefamulin, Moxifloxacin, Linezolid
- Where
- 99 sites in United States, Argentina and 16 more
- Volunteers
- 551 people
- Sponsor
- Nabriva Therapeutics AG
Community-acquired Pneumonia
Efficacy and Safety of SR1375 in Adult Patients With CAP
This is a phase 2 study to evaluate the efficacy and safety of SR1375 in hospitalized adult patients with CAP. Patients will receive SR1375 or placebo for 8 weeks. The study duration for each patient is up to 10 weeks.
- Trial name
- CAP (NCT06577558)
- Testing
- SR1375 capsule 3mg+regular treatments, SR1375 capsule 1mg+regular treatments, SR1375 capsule 0.3mg+regular treatments
- Where
- 29 sites in China
- Volunteers
- 240 people
- Sponsor
- Shanghai SIMR Biotechnology Co., Ltd.
Community-Acquired Pneumonia
Early Molecular Detection Technique Coupled With Urinary Test of Infectious Agents Responsible of Children CAP
Community-Acquired Pneumonia (CAP) of children are a recurrent pathology with multiple severity scores. The etiology is never really identified, and the initial treatment is always based on probabilistic antibiotics, in the case…
- Trial name
- OptiPAC (NCT02668237)
- Testing
- OptiPAC, Usual care
- Where
- 11 sites in France
- Volunteers
- 500 people
- Sponsor
- Centre Hospitalier Universitaire de Saint Etienne
Community Acquired Pneumonia in Children
Short Versus Standard of Care Antibiotic Duration for Children Hospitalized for CAP
The goal of this open label, randomized, non-inferiority clinical trial is to compare the treatment success of a 5 day antibiotic course versus a standard antibiotic course (usually 7-14 days of antibiotics) in hospitalized…
- Trial name
- NCT06494072
- Testing
- Ampicillin for Injection, Ceftriaxone for Injection, Amoxicillin
- Where
- United States
- Volunteers
- 236 people
- Sponsor
- Medical College of Wisconsin